Glutathione (GSH) and GSH-associated metabolism provide the major line of defense for the protection of cells from oxidative and other forms of toxic stress. Of the three amino acids that comprise GSH, cysteine is limiting for GSH synthesis. Since extracellularly cysteine is readily oxidized to form cystine, cystine transport mechanisms are essential to provide cells with cysteine. Cystine uptake is mediated by system x c − , a Na + -independent cystine/glutamate antiporter. Inhibition of system x c − by millimolar concentrations of glutamate, a pathway termed oxidative glutamate toxicity, results in GSH depletion and nerve cell death. Recently, we described a series of compounds derived from the conjugation of epicatechin with cysteine and cysteine derivatives that protected nerve cells in culture from oxidative glutamate toxicity by maintaining GSH levels. In this paper, we characterize an additional epicatechin conjugate, cysteamine-epicatechin, that is 5-10 fold more potent than the earlier conjugates. In addition, we show that these epicatechin conjugates maintain GSH levels by enhancing the uptake of cystine into cells through induction of a disulfide exchange reaction, thereby uncoupling the uptake from system x c − . Thus, these novel epicatechin conjugates have the potential to enhance GSH synthesis under a wide variety of forms of toxic stress.
is readily oxidized to form cystine, so for most cell types, cystine transport mechanisms are essential to provide them with the cysteine needed for GSH synthesis (Wu et al. 2004 ).
Cystine uptake in many types of cells is mediated by system x c − , a Na + -independent cystine/ glutamate antiporter (Sato et al. 1999) . System x c − is a member of the disulfide-linked heteromeric amino acid transporter family and consists of a light chain (xCT) that confers substrate specificity and a heavy chain (4F2hc) that is shared among a number of different amino acid transporters (Wagner et al. 2001) . It transports cystine into cells in a 1:1 exchange with glutamate and is thus inhibited by high concentrations of extracellular glutamate (Murphy et al. 1989) . The importance of system x c − for the maintenance of GSH levels in cells is demonstrated by the loss of GSH and subsequent cell death seen in nerve and other types of cells following exposure to millimolar concentrations of extracellular glutamate, a pathway termed oxidative glutamate toxicity or oxytosis (Tan et al. 2001) . Furthermore, mice that lack system x c − function, either via truncation (Shih et al. 2006) or deletion show brain atrophy and redox imbalance (Sato et al. 2005) , respectively.
GSH loss has been directly correlated with cell death following exposure of neural cells to a wide range of insults (Maher 2005) . In addition, GSH loss is associated with the cell death seen in a variety of neurological disorders including Parkinson's disease, Alzheimer's disease, and stroke (Bains & Shaw 1997 , Maher 2006 . Thus, treatments that can maintain GSH levels in the presence of a GSH loss-inducing stress have a significant potential for the treatment of neurological diseases.
Recently, we described a series of compounds derived from the conjugation of the flavonoid epicatechin with cysteine and cysteine-related molecules that were significantly more effective than the underivatized flavonoid at protecting nerve cells in culture from oxidative glutamate toxicity (Torres et al. 2005) . These compounds, which were obtained by acid depolymerization of proanthocyanidins in the presence of the thiol (Torres et al. 2002) , protect nerve cells by maintaining GSH levels rather than scavenging free radicals through their phenolic moieties (Torres et al. 2005) . However, they all had relatively low potencies with EC50 values ranging from 36-60 μM. In the work described below, we characterized an additional epicatechin conjugate, cysteamine-epicatechin (Cya-EC), that is 5-10 fold more potent than any of the earlier conjugates. In addition, we show that this novel epicatechin conjugate, as well as the previously described epicatechin conjugates, maintain GSH levels by enhancing the uptake of cystine/cysteine into cells by a mechanism that uncouples the uptake from system x c − . Thus, these flavonoid conjugates provide a novel mechanism for maintaining cellular redox homeostasis.
Experimental procedures Materials
Quisqualate was from Tocris. Homocysteic acid, cystine, cysteine, cysteamine, glutamate, 2-aminobicyclo(2,2,1)heptane-2-carboxylic acid (BCH), methylaminoisobutyric acid (MAIBA), L-β-threo-benzyl-aspartate (TBOA), arginine, L-serine and D-serine as well as all other chemicals were from Sigma.
Preparation of the thioconjugates
Conjugates of epicatechin, epigallocatechin, epicatechin gallate and epigallocatechin gallate with cysteamine, cysteine or cysteine derivatives were obtained by cleavage of polymeric flavanols (proanthocyanidins) essentially as described (Torres & Bobet 2001 , Lozano et al. 2006 . The sources of epicatechins and epigallocatechins were grape pomace and witch hazel stems, respectively. Briefly, the plant material was treated with the corresponding thiol in 0.25% aqueous HCl at 90°C for 2h. The resulting conjugates were purified by cation-exchange and reversed-phase liquid chromatography and characterized by electrospray mass spectrometry (ESI-MS), high resolution mass spectrometry (HR-MS) and nuclear magnetic resonance (NMR). ES-MS spectra were recorded on an Agilent 1100/API 3000 (Waldbronn, Germany) system and HR-MS spectra were recorded on a LC/MSD-TOF (Agilent Technologies, Santa Clara, CA) system. 1 H-NMR spectra were observed with an Inova-500 MHz (Varian, Palo Alto, CA) apparatus for (CD 3 )OD and D 2 O solutions. The analytical data for Cya-EC, Cya-ECG, Cys-EC, ECys-EC and AMCys-EC were measured and compared with those already published (Torres & Bobet 2001 , Lozano et al. 2006 . The analytical data for Cya-EGC and Cya-EGCG are reported here for the first time. 
4ß-(2-aminoethylthio) epigallocatechin (Cya-EGC)-ES-MS

Cell Culture and Viability Assays
HT22 cells were grown on tissue culture dishes in DMEM-high glucose supplemented with 10% FCS as described (Davis & Maher 1994) . Primary rat cortical neurons were prepared and grown as described (Maher 2001) . Cell viability was determined by a modified version of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay based on the standard procedure (Hansen et al. 1989) . The cells were plated into 96 well dishes at 5 × 10 3 cells/dish in complete medium and 18 hr later the medium was replaced with DMEM-high glucose supplemented with 7.5% dialyzed FCS (DFCS) and the experimental agents were added. In some experiments, cystine-free DMEM-high glucose supplemented with 7.5% DFCS was used in order to deplete cystine from cells. 24 hr after the addition of the experimental agents, the cell culture medium in each dish was aspirated and replaced with 100 μl DMEMhigh glucose with 7.5% DFCS containing 2.5 μg/ml MTT. After 4 hours of incubation at 37°C
, the cells were solubilized by the addition of 100 μl of a solution containing 50% dimethylformamide and 20% SDS (pH 4.7). The absorbance at 570 nm was measured on the following day with a microplate reader. Results obtained from the MTT assay correlated directly with the extent of cell death as confirmed visually. Controls employing wells without cells and cells without the experimental agents were used to determine the effects of agents upon the assay chemistry or cell viability, respectively.
Total Intracellular GSH/GSSG
Cells were washed twice with ice-cold PBS, collected by scraping, and lysed with 3% sulfosalicylic acid. Lysates were incubated on ice for 10 minutes and supernatants were collected after centrifugation in an Eppendorf microfuge. Upon neutralization of the supernatant with triethanolamine, the concentration of total glutathione (reduced and oxidized) was determined by the method of Tietze (Tietze 1969 ) with modifications (Ishige et al. 2001) . The protein content of each sample was determined using the BCA Protein Assay kit from Pierce (Rockford, IL) with BSA as a standard.
S-Cystine Uptake
Cells were plated into 24 well dishes at 3 × 10 5 cells/well. 24 hr later the cells were rinsed 3 times with sodium-free (sodium replaced with choline chloride) or sodium-containing Hank's Balanced Salt Solution (HBSS) and incubated with 25 μM 35 S-cystine (Amersham) for 10-60 min in the same buffer as used for washing. The uptake was terminated by placing the dish on ice and washing 3 times with ice-cold HBSS. The cells were solubilized by overnight incubation in 500 μl 0.2 M NaOH. The radioactivity in a 150 μl aliquot was determined by scintillation counting and normalized to protein determined using the Bradford Assay (Pierce).
Thiol exchange
Stock solutions of Cya-EC and L-Cystine (1 mg/ml) were used. L-Cystine (60 μl) was added to Cya-EC (120 μl) and taken up to a final volume of 5 ml with Hanks balanced solution. The final concentration of each compound was 50 μM. The solution was incubated at 37°C for 50 min. Samples were taken and kept frozen until the HPLC analysis.
Statistical Analysis
All statistical analyses were performed using InStat 3. The results were analyzed for statistically significant differences at the p < 0.05 level using the analysis of variance (ANOVA) test and Tukey's post test for individual group means comparisons. A minimum of three independent experiments were used for statistical analyses.
Results
Similar to the previously described epicatechin conjugates (Torres et al. 2005) (Table 1) , cysteamine-epicatechin (Cya-EC) dose dependently protected the HT22 nerve cell line (Fig.  1A ) from oxidative glutamate toxicity with an EC50 of ∼ 6 μM. Cya-EC also protected primary neurons from glutamate (Fig. 1B) . In addition, Cya-EC protected nerve cells from homocysteic acid and quisqualate (Fig. 1C) , two additional compounds that kill nerve cells by blocking cystine uptake through system x c − . The cysteine and cysteine derivative epicatechin conjugates were shown previously to protect cells via the maintenance of GSH levels (Torres et al. 2005) . Similarly, as shown in Figure 2A , Cya-EC dose-dependently maintains GSH levels in the presence of glutamate. Even after 8 hr of glutamate treatment when the levels of GSH have fallen below the critical 20% level, HT22 cells treated with 10 μM Cya-EC maintained at least 50% of the control level of GSH (Fig. 2B ). The effects of Cya-EC on both GSH levels and cell survival in glutamate-treated cells is blocked by treatment with BSO, an inhibitor of GSH synthesis (Griffith & Meister 1979) (Fig. 2C ), demonstrating that Cya-EC acts at or before GSH synthesis to increase GSH levels.
To understand how Cya-EC maintains GSH levels, we decided to examine its effects on each of the steps in GSH metabolism, beginning with cystine uptake. Surprisingly, we found that Cya-EC enhanced cystine uptake in a time- (Fig. 3A ) and dose-dependent ( Fig. 3B) manner.
There was an excellent correlation between increases in cystine uptake and increases in GSH levels ( Fig. 3C ). Furthermore, in contrast to the results with glutamate toxicity, Cya-EC failed to protect cells from cystine depletion (Fig. 3E ). In the uptake experiments, Cya-EC was mixed with 35 S-cystine and then added directly to the cells for the 60 min uptake time point or after incubation at 37°C for 10-50 min so that while the time for the treatment of the cells with the mixture ranged from 10-60 min, the total incubation time for the mixture was always 60 min. However, unexpectedly, when we began studies to tease out the mechanisms underlying the effect of Cya-EC on cystine uptake and used only a 10 min total incubation time, we saw no effect (data not shown). In contrast, if we pre-incubated Cya-EC with 35 S-cystine at 37°C before adding the mixture to the cells for 10 min, then the enhancement of cystine uptake was restored. Indeed, further studies showed a time dependent increase in 35 S-cystine uptake following pre-incubation with Cya-EC that reached a plateau after ∼50 min at 37°C (Fig. 3D) . These results suggested that there was a direct interaction between Cya-EC and cystine that was not instantaneous and perhaps generated a product that was transported into cells by a pathway distinct from system x c .
To examine the fate of Cya-EC upon incubation with cystine we mixed the compounds together in HBSS and analyzed the mixture by reversed-phase high performance liquid chromatography (RP-HPLC) at different times over a total period of 60 min. We observed a decrease in the peak corresponding to Cya-EC and the appearance of a new, small peak corresponding to the cysteine conjugate, Cys-EC (Fig 4) . The same behavior was observed with the dimer of Oethyl-cysteine (data not shown). These results indicate that the cysteamine moiety of Cya-EC can be replaced by other sulfur containing compounds which are present in the form of disulfides.
To provide evidence for the idea that sulfur-containing compounds distinct from cystine can be transported into cells upon treatment with Cya-EC, we first looked at the ability of glutamate and quisqualate to inhibit cystine uptake. In control cells, 5 mM glutamate or 250 μM quisqualate, a more specific inhibitor of system x c − , inhibited 35 S-cystine uptake by ∼80% (Fig. 5 ). In contrast, in cells treated with Cya-EC, both glutamate and quisqualate only reduced 35 S-cystine uptake by ∼30% (Fig. 5) .
If the interaction of Cya-EC with cystine results in the generation of cysteine and eventually, a mixed disulfide, cysteine could be taken up by cells through a variety of ubiquitously expressed Na + -independent and -dependent transport systems distinct from system x c − (Wagner et al. 2001 , Hyde et al. 2003 while mixed disulfides could be taken up by the Na + -independent system L (Ishii et al. 1981) . Indeed, high concentrations of cysteamine have been shown to increase 35 S-cystine uptake into cells by this mechanism (Issels et al. 1988) . To test this idea, we first looked at the ability of cysteine to block the Cya-EC-dependent increase in 35 S-cystine uptake into cells. In these experiments, cysteine was added to the mixture of Cya-EC and 35 S-cystine after the 50 min incubation period and immediately before the addition of the mixture to cells to preclude any effects on the interaction between Cya-EC and 35 Scystine. As shown in Figure 5 , 5 mM cysteine inhibited by 75% the Cya-EC dependent increase in 35 S-cystine uptake but had no effect on 35 S-cystine uptake in control cells. In contrast, 5 mM cystine inhibited by ∼85% 35 S-cystine uptake in control cells but had a much lesser effect on 35 S-cystine uptake in Cya-EC-treated cells (Fig. 5 ).
To determine which uptake systems for cysteine were responsible for the enhanced Cya-ECmediated uptake of 35 S-cystine, we tested inhibitors of each of the different uptake systems that have been shown to transport cysteine and/or the mixed disulfide for their effects on Cya-EC-stimulated 35 S-cystine uptake. Both system asc and system L can transport cysteine by Na + -independent mechanisms (Wagner et al. 2001 ) and system L can also transport mixed disulfides (Ishii et al. 1981) . However, only an inhibitor of system L (BCH) but not an inhibitor of system asc (D-serine) blocked the enhancement of Na + -independent 35 S-cystine uptake by Cya-EC (Fig. 6 ). System A, system ASC, EAATs and system B o,+ can transport cysteine by Na + -dependent mechanisms (Hyde et al. 2003) . However, while an inhibitor of system ASC (L-serine) blocked the enhancement of Na + -dependent 35 S-cystine uptake by Cya-EC, inhibitors of system A (methylaminoisobutyric acid (MAIBA)), EAATs (TBOA) and system B o,+ (arginine) had little or no effect. Although D-serine has been reported to inhibit system ASC, this inhibition is specific for ASCT2 (Shafqat et al. 1993 , Utsunomiya-Tate et al. 1996 while ASCT1 is the ASC transporter expressed in neurons (Yamamoto et al. 2004) .
To further validate these findings, we looked at the effects of the different inhibitors of cysteine transport on both Cya-EC-mediated increases in GSH and cell survival in the presence of glutamate. As shown in Figure 6 , only the system ASC inhibitor L-serine significantly decreased Cya-EC-mediated increases in GSH levels. L-serine also significantly decreased the effect of Cya-EC on cell survival in the presence of toxic concentrations of glutamate while inhibitors of the other transport systems, D-serine, MAIBA, TBOA and arginine, had little or no effect. BCH by itself increased GSH levels and cell survival in the presence of glutamate and so its effect on Cya-EC-mediated increases in GSH levels and protection from glutamate toxicity could not be evaluated.
If Cya-EC increases 35 S-cystine uptake by releasing cysteine from cystine through a mechanism involving the cleavage of cystine with the eventual formation of a mixed disulfide by the departing cysteamine moiety, then we would expect to see similar effects on 35 S-cystine uptake and cell survival with equivalent concentrations of cysteamine (Cya). As shown in Figure 7A , this is indeed the case. 10 μM Cya enhances 35 S-cystine uptake and this enhancement is inhibited by both L-serine and BCH but not by MAIBA, TBOA, arginine or Dserine (Fig. 7B) . Cya also protects cells from oxidative glutamate toxicity and this protection is inhibited by L-serine but not by MAIBA, TBOA, arginine or D-serine (Fig. 7B ).
Several other EC conjugates have been shown to increase GSH levels and cell survival in the HT22 cells (Torres et al. 2005 ). In addition, we made additional Cya conjugates including Cyaepicatechin gallate (Cya-ECG), Cya-epigallocatechin (Cya-EGC) and Cya-epigallocatechin gallate (Cya-EGCG) (Table 1) , to determine if modification of epicatechin affected the ability of the Cya conjugate to enhance GSH levels and protect cells from oxidative stress. While Cya-ECG was reasonably effective at enhancing GSH levels ( Fig. 8B ) and protecting HT22 cells from oxidative glutamate toxicity (Fig. 8B) , the other modifications led to significant reductions in potency and efficacy. Because the less effective cysteamine derivatives included moieties (ECG, EGC, EGCG) more active than EC at scavenging free radicals, these results confirmed our previous observation that scavenging of mitochondrial ROS does not play a significant role in the protection against oxidative glutamate toxicity by these particular kinds of compounds (Torres et al. 2005) . We also looked at the ability of the cysteamine conjugates, as well as the previously described EC conjugates (Cys-EC, AMCys-EC and ECys-EC) (Table  1) , to enhance cystine uptake. Using a fixed concentration of 10 μM, we found that Cya-EC was the most effective of all of the EC conjugates at increasing 35 S-cystine uptake although several of the other conjugates were also quite good including Cya-ECG (Fig. 8A) . In contrast, both Cya-EGC and Cya-EGCG were almost completely ineffective. The effects of the conjugates on 35 S-cystine uptake showed a good correlation with their effects on GSH levels strongly suggesting that they increase GSH levels by a mechanism very similar to that of Cya-EC.
Discussion
In these studies we describe a novel epicatechin derivative, Cya-EC, that enhances GSH levels and cell survival by increasing cystine uptake into cells. It does so not by increasing the activity of system x c − , but rather by reacting with cystine and releasing cysteine which can react with the leaving cysteamine moiety to form the mixed disulfide Cya-Cys (Fig. 9) , thereby allowing these sulfur-containing compounds to enter cells via multiple transport systems. We have preliminary data suggesting that the same reactions occur under physiological conditions. Cya-EC is partially converted into Cys-EC when absorbed and metabolized in the small intestine, probably through reaction with endogenous cystine (unpublished results).
Although a similar pathway was described for the enhancement of cystine uptake by cysteamine in CHO cells (Issels et al. 1988 ) and N-acetyl cysteine (Phelps et al. 1992) in pulmonary artery endothelial cells, relatively high concentrations of cysteamine (0.4 mM) or NAC (1 mM) were required for an effect to be seen in these studies. In contrast, we find that Cya-EC is effective below 10 μM. However, in our system we also see a strong effect of cysteamine at this concentration. Nevertheless, we believe that Cya-EC provides a better option for enhancing cystine uptake into cells than cysteamine for several reasons. First, the presence of the polyphenol group in Cya-EC is likely to modify the ability of the compound to cross the blood-brain barrier or the blood-retina barrier, thereby allowing it access to two tissues, the brain and the eye, where the ability to maintain GSH levels is of utmost importance. Indeed, a glucuronidated and methylated metabolite of epicatechin has been detected in the brains of rats and mice after oral ingestion of the intact polyphenol (El-Mohsen et al. 2002 , van Praag et al. 2007 ). This metabolite may be involved in the retention of spatial memory in mice fed with EC (van Praag et al. 2007) . While there could be some problems with Cya-EC crossing membranes due to its charge, we also saw significant effects on 35 S-cystine uptake with uncharged cysteine derivatives such as AMCys-EC. Second, solutions of cysteamine tend to oxidize. Cystamine, the oxidized form of cysteamine, is much less effective at promoting cystine uptake (Wood et al. 2007) . In contrast, cysteamine in the form of the epicatechin conjugate cannot oxidize because it does not have a free thiol group. Furthermore, Cya-EC is a potent inhibitor of bacterial lipopolysaccharide (LPS)-induced cytokine production (Mitjans et al. 2004) , a model for anti-inflammatory activity, with > 80% inhibition seen at 70 μM whereas a similar level of anti-inflammatory activity was only seen in the presence of millimolar concentrations of cysteamine (Ozaki et al. 2007 ).
The ability to enhance cystine uptake by converting it to cysteine and thereby shifting its uptake to alternative transport systems could have a number of potential benefits. First, as indicated in the Introductory Statement, system x c − is an antiporter, expelling one molecule of glutamate for every molecule of cystine taken up into cells. There are a number of conditions, especially in the brain, where increases in extracellular glutamate are not desirable because of its interaction with ionotropic glutamate receptors. Therefore, a mechanism for increasing cysteine, the rate limiting precursor for GSH synthesis, without increasing extracellular glutamate, could be highly beneficial (e.g. Piani & Fontana 1994 , Fogal et al. 2007 . Second, when brain glutamate is high, cystine uptake through system x c − is inhibited. The EC derivatives allow cells to bypass this system. Furthermore, since cysteine uptake can occur through a number of different transporters, it is less likely to be impacted by a specific insult. Third, system x c − works in conjunction with glutamate transporters (Lewerenz et al. 2006 ).
Glutamate transporters have been shown to be quite sensitive to oxidative stress (Trotti et al. 1998) . Thus, under conditions where it may be critical to increase GSH levels, system x c − may not function efficiently. Cya-EC could provide an alternative for maintaining the cysteine needed for GSH synthesis. Fourth, Cya-EC might be particularly useful under conditions of lactacidosis which occurs during ischemia, head trauma, hyperglycemia and seizures (Lipton 1999) . System x c − is impaired under these conditions (Bannai & Kitamura 1981 , Koyama et al. 2000 , potentially leading to a deficiency in cystine uptake across the blood-brain barrier where xCT expression is highest (Burdo et al. 2006) . Cya-EC could ameliorate this impairment and would not have to cross the blood-brain barrier to do so.
Cysteamine is neuroprotective in a variety of in vitro and in vivo models of neurodegenerative diseases (for review see Wood et al. 2007) . Although a number of mechanisms underlying this neuroprotection have been proposed, it is likely that an important aspect is the ability of cysteamine to increase intracellular thiol pools. This, in turn, will enhance the synthesis of GSH and may also have additional protective effects (Wood et al. 2007 ).
The ability of cysteamine to react with cystine to produce cysteine and a mixed disulfide is well known (Meier & Issels 1995) . Other thiols share this property (Meier & Issels 1995) , but all of these compounds contain a free thiol group. Indeed, oxidation of the thiol or addition of a phosphate group abolished the ability of the compounds to promote cystine uptake (Meier & Issels 1995) . It is therefore somewhat surprising that the Cya-EC conjugate is able to promote cystine uptake. However, the studies with the different cysteamine-epicatechin conjugates suggest that epicatechin allows the cysteamine to readily react with disulfides but other epicatechin-related compounds do not appear to be as effective at transferring their attached sulfur-containing moiety.
Using inhibitors of a variety of ubiquitously expressed Na + -independent and -dependent transport systems that are known to transport cysteine into cells, we found that only inhibitors of the Na + -independent system L and the Na + -dependent system ASC altered the increase in cyst(e)ine uptake promoted by treatment of the HT22 cells with Cya-EC. This is somewhat surprising in that other studies that looked at the mechanisms underlying cysteine uptake in nerve cells showed that glutamate transporters (EAATs) provided the major route for transport (Shanker et al. 2001 , Chen & Swanson 2003 . While EAATs are expressed by the HT22 cells (Lewerenz et al. 2006 ) both glutamate and the EAAT inhibitor, TBOA, had little or no effect on cyst(e)ine transport. However, since Cya-EC is also able to promote the survival of primary neurons in response to glutamate treatment it is unlikely that the promotion of cysteine transport by Cya-EC is specific to HT22 cells.
In summary, we have characterized an epicatechin derivative that increases GSH synthesis and protects cells from oxidative stress by virtue of its ability to enhance cystine uptake through its conversion to cysteine and eventually a mixed disulfide. This allows uptake through a variety of pathways which are not subject to the same problems and constraints as system x c − . Thus, this derivative has the potential to enhance GSH synthesis under a wide variety of forms of toxic stress. Cysteine but not glutamate or quisqualate inhibit Cya-EC-mediated 35 S-cystine uptake. Cells were treated with 25 μM 35 S-cystine alone or in the presence of 10 μM Cya-EC along with either 5 mM glutamate, 250 μM quisqualate, 5 mM cysteine or 5 mM cystine, added to the labeling mixture just before addition to the cells for 10 min. After solubilization of the cells in 0.2 M NaOH, aliquots were taken for scintillation counting and protein determination. Results are presented as the percent of uptake in the absence of glutamate, quisqualate, cysteine or cystine. Similar results were obtained in three independent experiments. * indicates significantly different from control. Effects of cysteine transporter inhibitors on Cya-EC-mediated increases in 35 S-cystine uptake and the maintenance of GSH levels and cell survival in glutamate-treated HT22 cells. For the measurement of 35 S-cystine uptake, cells were treated with 25 μM 35 S-cystine in the presence of 10 μM Cya-EC alone or along with 5 mM BCH, 5 mM D-serine, 5 mM arginine, 5 mM serine, 100 μM TBOA or 5 mM MAIBA which were added to the labeling mixture just before addition to the cells for 10 min. After solubilization of the cells in 0.2 M NaOH, aliquots were taken for scintillation counting and protein determination. For the measurement of GSH, cells were treated with 5 mM glutamate alone or in the presence of 10 μM Cya-EC alone or along with 5 mM BCH, 5 mM D-serine, 5 mM arginine, 5 mM serine, 100 μM TBOA or 5 mM MAIBA. GSH levels were measured after 8 hr by a chemical assay and normalized to total protein. For the measurement of cell survival, cells were treated with 5 mM glutamate alone or in the presence of 10 μM Cya-EC alone or along with 5 mM BCH, 5 mM D-serine, 5 mM arginine, 5 mM serine, 100 μM TBOA or 5 mM MAIBA. Cell survival was measured after 24 hr by the MTT assay. Results are the average ± SEM of three independent experiments. * indicates significantly different from Cya-EC alone. Effect of cysteamine (Cya) on cell survival (A) and 35 S-cystine uptake and cell survival in glutamate-treated HT22 cells (B). For the measurement of cell survival, cells were treated with 5 mM glutamate alone or in the presence of increasing doses of (A) Cya or (B) 10 μM Cya alone or along with 5 mM BCH, 5 mM D-serine, 5 mM arginine, 5 mM serine, 100 μM TBOA or 5 mM MAIBA. Cell survival was measured after 24 hr by the MTT assay. For the measurement of 35 S-cystine uptake, cells were treated with 25 μM 35 S-cystine in the presence of 10 μM Cya alone or along with 5 mM BCH, 5 mM D-serine, 5 mM arginine, 5 mM serine, 100 μM TBOA or 5 mM MAIBA which were added to the labeling mixture just before addition to the cells for 10 min. After solubilization of the cells in 0.2 M NaOH, aliquots were taken for scintillation counting and protein determination. Results are the average ± SEM of three independent experiments. * indicates significantly different from Cya alone. Effect of different EC conjugates on 35 S-cystine uptake (A) and the maintenance of GSH levels and cell survival in glutamate-treated HT22 cells (B). For the measurement of 35 S-cystine uptake, cells were treated with 25 μM 35 S-cystine in the presence of 10 μM of each of the conjugates or EC for 10 min following a 50 min pre-incubation at 37°C. After solubilization of the cells in 0.2 M NaOH, aliquots were taken for scintillation counting and protein determination. For the measurement of GSH, cells were treated with 5 mM glutamate alone or in the presence of 10 μM of each of the conjugates. GSH levels were measured after 8 hr by a chemical assay and normalized to total protein. For the measurement of cell survival, cells were treated with 5 mM glutamate alone or in the presence of 10 μM of each of the conjugates. Cell survival was measured after 24 hr by the MTT assay. Results are the average ± SEM of three independent experiments. * indicates significantly different from glutamate alone. Proposed mechanism for the conversion of cystine to cysteine and a mixed disulfide by Cya-EC.
